Optimising malignant melanoma management in Europe
EUMelaReg collects health information to improve care and treatment for patients with skin cancer
Sustaining and fostering collaboration between academia and industry
for the collection of baseline, treatment and outcome data of representative samples of malignant melanoma patients of major European countries.
Building the largest and quickest melanoma registry in the world
EUMelaReg collects real-world data on melanoma patients throughout Europe and integrates them in a data warehouse.



ESMO 2023: Efficacy of immune checkpoint inhibition in metastatic or nonresectable melanoma after failure of adjuvant anti PD1 treatment - A EUMelaReg real world evidence study
Authors: M. Weichenthal, D. Schadendorf, L. Bastholt et al.
EADO 2023: Modern Treatment Usage and Outcome of Patients with Advanced and High risk Non Melanoma Skin Cancer (NMSC) a Registry Based Cohort Study
Authors: M. Weichenthal, P. Ascierto, N. Asher et al.


ASCO 2022: EMRseq: Registry based outcome analysis on 1,000 patients with BRAF V600 mutated metastatic melanoma in Europe treated with either immune checkpoint or BRAF/MEK inhibition
Authors: L. Bastholt, I.M. Svane, D. Schadendorf et al.
EADO 2022: Combi-EU: BRAF-/MEK-Inhibition with Dabrafenib and Trametinib in Melanoma Patients in the Adjuvant Setting: Interim Analysis of an Observational Study on a Treatment supporting Electronic Health App.
Authors: M. Weichenthal, P. Mohr, E. Livingstone et al.
ESMO 2022: Outcome of PD 1 Inhibitor Therapy of Advanced Melanoma Patients according to Demographic Factors in a Real World Setting across Europe
Authors: M. Weichenthal, I.M. Svane, L. Kandolf Sekulovic